Medication info
Lokan Duo Tablet 20/32 Milligrams

Lokan Duo Tablet 20/32 Milligrams

Prescription medicationTabletOral
Ingredient · strength
Rosuvastatin Calcium›20.8mg / 1 tabletCandesartan Cilexetil›32mg / 1 tablet
Manufacturer / importer
Albogen Korea Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets (10 tablets/PTP X 3)
Approval status
Active

MFDS item code 201702398 · Approved 2017.05.16 · Insurance code 652606350

Summary

Main use
Treatment of hypertension and heart failure, improvement of hyperlipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment options should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.
Child dose
The safety and efficacy in adolescents and children 18 years of age or younger have not been established. The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Ingredients

Manufacturer
Albogen Korea Co., Ltd.

Efficacy & effects

Treatment of hypertension and heart failure, improvement of hyperlipidemia, and suppression of the progression of atherosclerosis and cardiovascular risk

  • Essential hypertension
  • left ventricular systolic dysfunction
  • primary hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • early coronary artery disease family history
View approved original text

This medication is used for patients who need to take Candesartan Cilexetil and Rosuvastatin together. Candesartan Cilexetil is used for the treatment of essential hypertension and in cases where patients with heart failure have a decrease in left ventricular function need additional treatment to ACE inhibitors or cannot tolerate them. Rosuvastatin is used mainly as an adjunct when dietary therapy is ineffective in patients with hypercholesterolemia and dyslipidemia. Furthermore, it helps lower blood cholesterol to delay the progression of atherosclerosis, reduce the risk of cardiovascular disease, and especially reduce the risk of stroke, myocardial infarction, and grafting risk in high-risk groups with elevated high-sensitivity C-reactive protein levels. This medication is used to improve both hypertension and cardiovascular disease risk factors simultaneously.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the efficacy and tolerability of each component, candesartan cilexetil and rosuvastatin. ○ Candesartan cilexetil 1. Essential hypertension 1) Adults: The recommended initial and maintenance dose is 8 ∼ 16 mg of candesartan cilexetil orally once daily. If blood pressure is not adequately controlled after 4 weeks of treatment with 16 mg once daily, the dose may be increased to a maximum of 32 mg once daily. If blood pressure is still not controlled at this dose, other treatment options should be considered. The maximum effect is achieved within 4 weeks of starting treatment. 2) Elderly patients: No adjustment of the initial dose is necessary. 3) Patients with intravascular volume depletion: In patients at high risk of hypotension, such as those with volume depletion, administer an initial dose of 4 mg with careful monitoring. 4) Patients with renal impairment: The initial dose for patients with renal impairment, including those on hemodialysis, is 4 mg; adjust the dose according to the patient's response. There is limited experience in patients with severe or end-stage renal impairment (creatinine clearance < 15 mL/min). 5) Patients with hepatic impairment: The initial dose for patients with mild to moderate hepatic impairment is 2 mg once daily; adjust the dose according to the patient's response. There is no experience in patients with severe hepatic impairment. 2. Heart failure 1) Adults: An initial dose of 4 mg once daily is recommended. The dose may be doubled at intervals of at least 2 weeks and increased to a maximum of 32 mg once daily, taking the patient's tolerability into consideration. 2) Elderly patients, patients with intravascular volume depletion, patients with renal impairment, and patients with mild to moderate hepatic impairment: No adjustment of the initial dose is necessary. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to a maintenance dose. The maintenance dose is 10 milligrams once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted as appropriate at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and the patient's response; it may be increased to a maximum of 20 milligrams daily. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race: Since systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose of this medicine is contraindicated in some of these patients. Patients taking candesartan cilexetil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience of administration.

Child dose

The safety and efficacy in adolescents and children 18 years of age or younger have not been established. The safety and efficacy in adolescents and children 18 years of age or younger have not been established.

Precautions

This medication can cause serious harm to the fetus, particularly when taken during the second and third trimesters of pregnancy. Therefore, it should be discontinued immediately if pregnancy is confirmed. This medication should not be used in patients with specific diseases, such as those with severe liver dysfunction, significantly impaired kidney function, or certain muscle diseases. This medication should be used with caution in the elderly or in patients with high potassium levels, and those with mild liver dysfunction, requiring regular blood tests and monitoring of physical condition. Muscle-related side effects may occur, so if symptoms like muscle pain or weakness appear, a doctor should be consulted immediately, and in severe cases, the medication should be discontinued. This medication can also affect liver function; therefore, it is important to conduct regular liver function tests both before and during treatment. There may be interactions with other medications, so be sure to inform medical staff of any other medications being taken, especially when used in combination with certain antibiotics, antifungals, immunosuppressants, and fibrate class drugs. Women of childbearing potential should use appropriate contraception while taking this medication, and nursing mothers are advised to avoid taking this drug. Safety and efficacy have not been established in children and therefore should not be recommended. In cases of overdose, appropriate treatment is required according to symptoms, and since this drug is not removed by hemodialysis, professional medical management is necessary. Dizziness or fatigue may occur while taking this medication, so caution should be exercised when driving or operating machinery. Keep this medicine out of the reach of children and store it in its original container to prevent misuse.

Side effects

headache, nasopharyngitis, localized infection, fatigue, systemic itching, pruritus, joint stiffness, limb pain, photophobia, indigestion, moles, periodontitis, inflammation, musculoskeletal pain, neck pain, elevated blood sugar, decreased serum sodium, hand fracture, hypoglycemia, nephrolithiasis, cough, tooth extraction, dizziness, positional vertigo, chest discomfort, nausea, generalized pain, muscle cramps, gout, erectile dysfunction, increased blood pressure, orthostatic hypotension, cerebral infarction, spondyloarthritis myelopathy, musculoskeletal discomfort, pneumonia, contusion, femoral fracture, unstable angina, idiopathic pulmonary fibrosis, wet cough, exacerbation of hypertension, unstable blood pressure, vertigo, positional vertigo, adrenal insufficiency, paralysis, tension increase, syncope, facial flushing, weight gain, facial swelling, thirst, sleep disorders, decreased libido, amnesia, loss of appetite, increased appetite, tinnitus, taste disturbance, erectile dysfunction, constipation, abdominal pain, pancreatitis, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, angioedema, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptom drug reaction syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, memory decline, amnesia, cognitive impairment, confusion

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is best to maintain a storage temperature between 1 and 30 degrees Celsius to preserve the effectiveness and safety of the medication for an extended period.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.